Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Heme Oxygenase-1 and Carbon Monoxide, Chronic Myeloid Leukemia Treatments, and Hematopoietic Stem Cell Transplantation.
Phase I/IIa clinical study of 4th generation BTK inhibitor HBW-3220 capsules in patients with B-cell malignancies.
Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications
Safety and efficacy of jaktinib (a novel<scp>JAK</scp>inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A<scp>single‐arm</scp>,<scp>open‐label</scp>, phase 2, multicenter study
S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.
Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study
P1033: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
Role of Hippocampal β-Adrenergic and Glucocorticoid Receptors in the Novelty-Induced Enhancement of Fear Extinction
Delayed Noradrenergic Activation in the Dorsal Hippocampus Promotes the Long-Term Persistence of Extinguished Fear
A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma
Stress within a Restricted Time Window Selectively Affects the Persistence of Long-Term Memory